Business Description
Neurocrine Biosciences Inc
NAICS : 325414
SIC : 2836
ISIN : US64125C1099
Share Class Description:
FRA:NB3: Ordinary SharesCompare
Compare
Traded in other countries / regions
NBIX.USAN1BI34.Brazil0K6R.UKNB3.Germany IPO Date
1996-05-23Description
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.37 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | 1.03 | |||||
Interest Coverage | 98 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 9.55 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.4 | |||||
3-Year EBITDA Growth Rate | 32.8 | |||||
3-Year EPS without NRI Growth Rate | -11.5 | |||||
3-Year FCF Growth Rate | 17.2 | |||||
3-Year Book Growth Rate | 23.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | 33.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 16.28 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 79.7 | |||||
9-Day RSI | 72.83 | |||||
14-Day RSI | 66.92 | |||||
6-1 Month Momentum % | 5.55 | |||||
12-1 Month Momentum % | 48.98 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.52 | |||||
Quick Ratio | 2.47 | |||||
Cash Ratio | 1.7 | |||||
Days Inventory | 319.54 | |||||
Days Sales Outstanding | 76.87 | |||||
Days Payable | 911.71 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | -0.73 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 98.05 | |||||
Operating Margin % | 23.73 | |||||
Net Margin % | 18.65 | |||||
FCF Margin % | 31.06 | |||||
ROE % | 18.2 | |||||
ROA % | 12.71 | |||||
ROIC % | 22.75 | |||||
ROC (Joel Greenblatt) % | 139.27 | |||||
ROCE % | 20.59 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 40.62 | |||||
Forward PE Ratio | 30.21 | |||||
PE Ratio without NRI | 36.32 | |||||
Shiller PE Ratio | 311.6 | |||||
Price-to-Owner-Earnings | 39.19 | |||||
PEG Ratio | 0.9 | |||||
PS Ratio | 7.57 | |||||
PB Ratio | 6.21 | |||||
Price-to-Tangible-Book | 6.31 | |||||
Price-to-Free-Cash-Flow | 24.36 | |||||
Price-to-Operating-Cash-Flow | 23.2 | |||||
EV-to-EBIT | 29.78 | |||||
EV-to-Forward-EBIT | 21.6 | |||||
EV-to-EBITDA | 28.44 | |||||
EV-to-Forward-EBITDA | 22.3 | |||||
EV-to-Revenue | 7.13 | |||||
EV-to-Forward-Revenue | 6.37 | |||||
EV-to-FCF | 23.01 | |||||
Price-to-Projected-FCF | 2.83 | |||||
Price-to-Graham-Number | 3.19 | |||||
Price-to-Net-Current-Asset-Value | 20.79 | |||||
Price-to-Net-Cash | 118.78 | |||||
Earnings Yield (Greenblatt) % | 3.36 | |||||
FCF Yield % | 4.14 |